Aging is inevitable. Feeling many
of the effects can be preventable.
And we’re working to make it doable.
We’re advancing our three founders’ mission with all we’ve got. Here’s who we are:
A business and scientific leader in pharmaceutical and biotechnology R&D, Dr. Moore has devoted his 25-year career to championing new chemical entities from discovery to the clinic (the pharmaceutical industry ‘Valley of Death’) for the treatment of asthma, osteoporosis, inflammatory diseases, and particularly oncology. Dr. Moore has held key positions such as Chief Executive Officer, President, Director and Chief Scientific Officer for companies that include Arris, Axys, Locus Pharmaceuticals, and most recently, Innocrin Pharmaceuticals (2014-2017). Dr. Moore’s responsibilities have included the evolution of corporate strategy, business development, management of external alliances, intellectual property, fundraising and all aspects of R&D and technology innovation.
Dr. Moore has a B.S. degree in chemistry from Southeastern Massachusetts University, a Ph.D. degree in chemistry from Brown University and, prior to joining the pharmaceutical industry, was a Winston Fellow and Assistant Professor in Biochemistry at Cornell University Medical College.
Dr. George Cox brings more than 30 years of combined science and legal experience to Vizuri Health Sciences. Prior to joining Vizuri, Dr. Cox was in private practice at IP & Business Law Counseling, LLC. Before attending law school, he enjoyed a 20-year career as a biomedical scientist and medical school professor at the National Cancer Institute and the Uniformed Services University of the Health Sciences. He’s authored more than 70 publications in diverse scientific disciplines including pharmacology, immunology, biochemistry, and cell and molecular biology.
Dr. Cox earned his B.A. degree in chemistry and zoology from Ohio Wesleyan University, his Ph.D. degree in pharmacology from The Ohio State University College of Medicine, and his J.D. degree from The American University Washington College of Law.
Mike is a leader skilled in project management, problem-solving, cross-functional team building, and change management. He led a group of project managers supporting contract development and manufacturing of biopharmaceuticals in his latest position as Vice President, Project Management for Paragon Bioservices. Previously, Mike served as Senior Director, Project Management for DSM Nutritional Products (formerly Martek Biosciences) where he established and ran a Project Management Office primarily responsible for new product development and operations projects. He was also instrumental in the integrations of both Martek Biosciences and Ocean Nutrition Canada into DSM following their acquisitions. Prior to joining DSM, Mike was a project manager in roles of increasing responsibility with MedImmune, Inc. and Baxter Healthcare Corporation.
Mike holds a B.S. in Chemistry from Illinois State University and a M.S. in Biotechnology from The Johns Hopkins University.
Chris brings more than 39 years of combined science and regulatory experience to Vizuri Health Sciences. Prior to joining Vizuri, Chris has held roles of increasing responsibility in Regulatory Affairs, Quality Assurance and Pharmacovigilance starting with the Upjohn Company, progressing to Glaxo Inc. and Purdue Pharma LP as well as in small Biotech start-ups. His therapeutic area experience includes metabolism and endocrine, cardiovascular, analgesia, anesthesia, dermatology, and CNS. His product development experience includes solid oral dosage forms, soft gelatin capsules, liquids, creams, ointments, aerosol delivery systems, sterile products, therapeutic proteins and cell-based therapies.
Chris hold a B.S. in Pharmacy from Purdue University and an MBA from Western Michigan University.
Dr. Matt Sharp brings more than 25 years of pharmaceutical product development experience to Vizuri Health Sciences. Prior to joining Vizuri he was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Innocrin Pharmaceuticals. Previously, he held a number of positions of increasing responsibility with GlaxoSmithKline (GSK), most recently serving as U.S. Head of Process Robustness and 2nd Generation, Active Pharmaceutical Ingredients (APIs). In these roles he was responsible for the development and manufacture of APIs as well as finished drug products. He has extensive experience in the manufacturing of drug products, research and development, process development, cGMP manufacturing, analytical development and quality systems.
In preparation for his pharmaceutical career, Matt received a B.Sc. degree in Chemistry from Sheffield City (England) Polytech, a M.Sc. in Organic Chemistry from the University of Waterloo (Canada), a Ph.D. in Organic Chemistry from the University of California, Irvine, and then trained as postdoctoral research fellow at the University of California, Berkeley.
Tim Warneke has more than 30 years of pharmaceutical development experience in clinical operations. These experiences range across large (Ciba-Geigy and Abbott Laboratories) to mid-size (King Pharmaceuticals) pharmaceutical companies and the world’s largest contract research organization (Quintiles, now IQVIA). Tim has leveraged his expert knowledge of the Code of Federal Regulations, ICH Guidelines, Good Clinical Practice to provide operational excellence in support of numerous INDs and NDAs throughout his career. Operationally focused, he has been responsible for clinical study conduct across all phases of pharmaceutical development from single-center studies to large multi-national clinical trials over a wide array of therapeutic areas. Tim began his career at Northwestern University in the Department of Community Health and Preventive Medicine coordinating the clinical activities of the landmark NHLBI funded CARDIA study from its initial year in 1983 to 1988.
Tim holds a B.S. in Education and M.S in Exercise Physiology from Eastern Illinois University.
Jon Golec has over 14 years of experience in a corporate accounting environment. Currently, Jon leads the accounting and finance functions for Vizuri Health Sciences LLC. As the Director of Finance, Jon partners with the CEO and executive team and guides the organization by providing valuable insight into core financial activities ranging from budgeting, cash flow management, and tax compliance.
Previously, Jon served as a Development Accountant where he collaborated with numerous project teams delivering prominent real estate projects throughout the Mid-Atlantic region. In this capacity, Jon monitored and maintained financials for numerous development projects communicating results to senior executives.
Jon holds a B.S. in Finance from Penn State University and an MBA from George Mason University.
John P. Walker, has spent his career in Healthcare. He started at American Hospital Supply Corporation, where he eventually became President of the Hospital Company, the largest operating unit of the Corporation. He then moved to the Bay Area, where over the last 30 years, he’s been Chairman, Executive Chairman or CEO of a number of companies including Vitaphore Corporation (sold to Union Carbide), Arris (AXYS) Pharmaceuticals (sold to Celera), Kai Pharmaceuticals (sold to Amgen), Guava Technologies (sold to Millipore Corporation), Signal Pharmaceuticals, (sold to Celgene), Novacea Corporation (merged with Transcept) and iPierian Corporation (sold to BMS). Most recently, John was a founder and Managing Director of Four Oaks Partners, a business advisory firm. He currently serves on the BOD of Lucile Packard Children’s Hospital at Stanford, Packard Children’s Health Alliance, and Random Acts of Flowers, a non-profit that repurposes flowers for delivery to patients at hospitals and long term care facilities.